THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS
Apremilast (AP) is a new phosphodiesterase 4 inhibitor for the treatment of psoriasis and psoriatic arthritis (PsA). Treatment with AP reduces the level of proinflammatory cytokines and the activity of inflammatory changes.The positive impact of AP treatment on the course of psoriasis has been pro...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2016-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2304 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849243339079024640 |
|---|---|
| author | Yu. L. Korsakova L. N. Denisov |
| author_facet | Yu. L. Korsakova L. N. Denisov |
| author_sort | Yu. L. Korsakova |
| collection | DOAJ |
| description | Apremilast (AP) is a new phosphodiesterase 4 inhibitor for the treatment of psoriasis and psoriatic arthritis (PsA). Treatment with AP reduces the level of proinflammatory cytokines and the activity of inflammatory changes.The positive impact of AP treatment on the course of psoriasis has been proven in a number of clinical trials, for example ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), in which the treatment with AP has led to a decrease in PASI scores in patients with moderate and severe psoriasis en plaque: after 16 weeks, a 75% PASI improvement was significantly more common in patients taking AP 30 mg twice daily (33%) than in those who used placebo (PL) (5%) (p = 0.0001). In the PALACE 1 trial, the PsA patients were given AP at a dose of 20 or 10 mg twice daily. At 16 weeks, the patients who used AP at doses 20 and 30 mg twice daily, more frequently showed a 20% improvement according to the American College of Rheumatology (ACR) response criteria (ACR20) than those who received PL (in 30.4, 38.1, and 19% of cases; p = 0.0166 and p = 0.0001, respectively). Following 52 weeks of AP treatment, ACR20 was achieved by 63.0% of the patients who took the drug at 20 mg twice daily, and by 54.6% of those who used 30 mg twice daily. The PALACE 1, PALACE 2, and PALACE 3 trials demonstrated that the most common adverse events (AE) were diarrhea, nausea, headache, upper respiratory tract infections, and nasopharyngitis. Most AE were mild and moderate; and the rate of therapy discontinuation due to AE was low.These PALACE trials covering 1493 patients have provided evidence for the efficacy and safety of AP in treating moderate PsA activity. |
| format | Article |
| id | doaj-art-7ceb1a37074c4b8da34156c38b2d0997 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2016-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-7ceb1a37074c4b8da34156c38b2d09972025-08-20T03:59:31ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922016-12-0154557257710.14412/1995-4484-2016-572-5772166THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITISYu. L. Korsakova0L. N. Denisov1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyApremilast (AP) is a new phosphodiesterase 4 inhibitor for the treatment of psoriasis and psoriatic arthritis (PsA). Treatment with AP reduces the level of proinflammatory cytokines and the activity of inflammatory changes.The positive impact of AP treatment on the course of psoriasis has been proven in a number of clinical trials, for example ESTEEM 1 (Efficacy and Safety Trial Evaluating the Effects of apreMilast in psoriasis), in which the treatment with AP has led to a decrease in PASI scores in patients with moderate and severe psoriasis en plaque: after 16 weeks, a 75% PASI improvement was significantly more common in patients taking AP 30 mg twice daily (33%) than in those who used placebo (PL) (5%) (p = 0.0001). In the PALACE 1 trial, the PsA patients were given AP at a dose of 20 or 10 mg twice daily. At 16 weeks, the patients who used AP at doses 20 and 30 mg twice daily, more frequently showed a 20% improvement according to the American College of Rheumatology (ACR) response criteria (ACR20) than those who received PL (in 30.4, 38.1, and 19% of cases; p = 0.0166 and p = 0.0001, respectively). Following 52 weeks of AP treatment, ACR20 was achieved by 63.0% of the patients who took the drug at 20 mg twice daily, and by 54.6% of those who used 30 mg twice daily. The PALACE 1, PALACE 2, and PALACE 3 trials demonstrated that the most common adverse events (AE) were diarrhea, nausea, headache, upper respiratory tract infections, and nasopharyngitis. Most AE were mild and moderate; and the rate of therapy discontinuation due to AE was low.These PALACE trials covering 1493 patients have provided evidence for the efficacy and safety of AP in treating moderate PsA activity.https://rsp.mediar-press.net/rsp/article/view/2304ampremilastphosphodiesterase 4 inhibitorpsoriasispsoriatic arthritis |
| spellingShingle | Yu. L. Korsakova L. N. Denisov THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS Научно-практическая ревматология ampremilast phosphodiesterase 4 inhibitor psoriasis psoriatic arthritis |
| title | THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS |
| title_full | THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS |
| title_fullStr | THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS |
| title_full_unstemmed | THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS |
| title_short | THE EFFICACY AND SAFETY OF THE NEW DRUG APREMILAST FOR THE TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS |
| title_sort | efficacy and safety of the new drug apremilast for the treatment of psoriasis and psoriatic arthritis |
| topic | ampremilast phosphodiesterase 4 inhibitor psoriasis psoriatic arthritis |
| url | https://rsp.mediar-press.net/rsp/article/view/2304 |
| work_keys_str_mv | AT yulkorsakova theefficacyandsafetyofthenewdrugapremilastforthetreatmentofpsoriasisandpsoriaticarthritis AT lndenisov theefficacyandsafetyofthenewdrugapremilastforthetreatmentofpsoriasisandpsoriaticarthritis AT yulkorsakova efficacyandsafetyofthenewdrugapremilastforthetreatmentofpsoriasisandpsoriaticarthritis AT lndenisov efficacyandsafetyofthenewdrugapremilastforthetreatmentofpsoriasisandpsoriaticarthritis |